Skip to main content
  • FDA Approves Second Biosimilar in Ophthalmology

    Coherus Biosciences announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar product to Lucentis (ranibizumab injection).

    An interchangeable product is a biosimilar product that meets additional FDA requirements, demonstrating that it is expected to produce the same clinical result as the reference product in any given patient.

    In anticipation of biosimilars entering the ophthalmology market, the Academy released a policy statement on biosimilar use in ophthalmic practices earlier this year.

    The Academy recognizes the potential societal value of biosimilars for improving the care of patients with eye disease and supports the use of biosimilars for their FDA-approved indications.